Immunization, Vaccines and Biologicals
The Immunization, Vaccines and Biologicals department is responsible for targeting vaccine-preventable diseases, guiding immunization research and establishing immunization policy.

Smallpox and mpox

Smallpox is an infectious disease caused by the variola virus of the Orthopoxvirus genus. The last known naturally transmitted case occurred in Somalia in 1977, and in 1980 WHO declared smallpox eradicated.

Mpox is an infectious disease caused by the monkeypox virus (MPXV) of the Orthopoxvirus genus. On 14 August 2024, the WHO Director-General declared the upsurge of mpox in the Democratic Republic of the Congo and other countries in Africa a Public Health Emergency of International Concern (PHEIC).

There are two licensed vaccines available for use in response to the current mpox outbreak: MVA-BN and LC16m8. WHO published a position paper in August 2024 providing policy recommendations for their use, followed by interim guidance outlining operational considerations for MVA-BN and LC16m8 vaccines. MVA-BN is a non-replicating smallpox and mpox vaccine that has been prequalified by WHO in September 2024 (with age extension in October 2024). LC16m8 is a minimally replicating smallpox and mpox vaccine, which was granted WHO Emergency Use Listing (EUL) in November 2024.

Publications

Smallpox and mpox 
(orthopoxviruses): WHO position paper, August 2024

This position paper is concerned with vaccines and vaccination against mpox and smallpox. Since the publication of the 2014 meeting report on smallpox...

MVA-BN (‎Modified Vaccinia Ankara – Bavarian Nordic)‎ smallpox and mpox vaccine: interim guidance, 27 November 2024

The MVA-BN (live Modified Vaccinia Ankara) vaccine is a third-generation smallpox vaccine, which contains a virus that cannot replicate in humans. The...

LC16m8 (‎live-attenuated freeze-dried vaccinia)‎ smallpox and mpox vaccine: interim guidance, 22 April 2025

LC16m8 vaccine (also known as LC16 or LC16 KMB) was developed as a third generation smallpox vaccine and more recently licensed for use against mpox. It...

This document helps programmes and partners implement data-driven and locally tailored strategies for the high uptake of mpox vaccination in outbreak settings....

WHO Q&A and FAQs

Additional resources